- Main
Discovery of 4-Piperazine Isoquinoline Derivatives as Potent and Brain-Permeable Tau Prion Inhibitors with CDK8 Activity.
- Grandjean, Jean-Marc;
- Jiu, Alexander;
- West, John;
- Aoyagi, Atsushi;
- Droege, Daniel;
- Elepano, Manuel;
- Hirasawa, Makoto;
- Hirouchi, Masakazu;
- Murakami, Ryo;
- Lee, Joanne;
- Sasaki, Koji;
- Hirano, Shimpei;
- Ohyama, Takao;
- Tang, Benjamin;
- Vaz, Roy;
- Inoue, Masahiro;
- Olson, Steven;
- Prusiner, Stanley;
- Conrad, Jay;
- Paras, Nick
- et al.
Published Web Location
https://doi.org/10.1021/acsmedchemlett.9b00480Abstract
Tau prions feature in the brains of patients suffering from Alzheimers disease and other tauopathies. For the development of therapeutics that target the replication of tau prions, a high-content, fluorescence-based cell assay was developed. Using this high-content phenotypic screen for nascent tau prion formation, a 4-piperazine isoquinoline compound (1) was identified as a hit with an EC50 value of 390 nM and 0.04 K p,uu. Analogs were synthesized using a hypothesis-based approach to improve potency and in vivo brain penetration resulting in compound 25 (EC50 = 15 nM; K p,uu = 0.63). We investigated the mechanism of action of this series and found that a small set of active compounds were also CDK8 inhibitors.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.
Main Content
Enter the password to open this PDF file:
-
-
-
-
-
-
-
-
-
-
-
-
-
-